![]() ![]() YOU ARE URGED TO READ THE JOINT PROXY STATEMENT/PROSPECTUS AND THE OTHER RELEVANT DOCUMENTS FILED WITH THE COMMISSION (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT QUIDEL, ORTHO AND THE PROPOSED TRANSACTION. This communication is not a substitute for the joint proxy statement/prospectus or registration statement or for any other document that Quidel and Ortho have filed or may file with the Commission in connection with the proposed transaction. Quidel and Ortho may also file other documents with the Commission regarding the proposed transaction. Each of Quidel and Ortho commenced mailing copies of the definitive joint proxy statement/prospectus to stockholders of Quidel and Ortho, respectively, on or about April 11, 2022. The registration statement, as amended, was declared effective by the Commission on April 11, 2022. 333-262434) with the Securities and Exchange Commission (the “Commission”) that contains a definitive joint proxy statement/prospectus and other relevant documents concerning the proposed transaction. (“Topco”), Topco has filed a registration statement on Form S-4 (File No. In connection with the proposed business combination transaction among Quidel, Ortho and Coronado Topco, Inc. View our story told by our people at Where You Can Find Additional Information ![]() For more information about Quidel, visit. Quidel’s mission is to provide patients with immediate and frequent access to highly accurate, affordable testing for the good of our families, our communities and the world. Under trusted brand names Sofia®, Solana®, Lyra®, Triage® and QuickVue®, Quidel’s comprehensive product portfolio includes tests for a wide range of infectious diseases, cardiac and autoimmune biomarkers, as well as a host of products to detect COVID-19. An innovator for over 40 years in the medical device industry, Quidel pioneered the first FDA-cleared point-of-care test for influenza in 1999 and was the first to market a rapid SARS-CoV-2 antigen test in the U.S. Quidel Corporation (Nasdaq: QDEL) is a leading manufacturer of diagnostic solutions at the point of care, delivering a continuum of rapid testing technologies that further improve the quality of health care throughout the globe. If the transaction is completed, Quidel stockholders are expected to own approximately 62% of the combined company and Ortho shareholders are expected to own approximately 38% of the combined company. Quidel stockholders will receive one share of the combined company common stock for each Quidel common share. Under the terms of the agreement by which Quidel will acquire Ortho, Ortho shareholders will receive $7.14 in cash and 0.1055 shares of the combined company common stock for each Ortho common share. We look forward to closing this transaction in the coming weeks and continue our work of improving patient outcomes across the globe,” said Douglas Bryant, President and Chief Executive Officer of Quidel. There is a lot of excitement across our teams about the opportunities that the combined company is expected to create, delivering innovative diagnostic solutions to our customers as well as the value that we plan to provide our shareholders. “We are incredibly pleased to have achieved this milestone and would like to thank all of our stockholders for their show of support. ![]() Following completion of the transaction, shares of the combined company will trade on the Nasdaq Global Select Market under the symbol "QDEL." The transaction is expected to close on May 27, 2022. Subject to sanction of a scheme of arrangement to be undertaken by Ortho under Part 26 of the UK Companies Act 2006 (the “Ortho Scheme”) by the High Court of Justice of England and Wales (the “Court”) and the delivery of the order of the Court sanctioning the Ortho Scheme to the registrar and the satisfaction of other customary closing conditions, Quidel will acquire Ortho, and Quidel and Ortho will become wholly owned subsidiaries of the combined company, upon the closing of the transaction. SAN DIEGO-( BUSINESS WIRE)-Quidel Corporation (Nasdaq: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that the previously announced acquisition of Ortho Clinical Diagnostics Holdings plc (“Ortho”) by Quidel and subsequent business combination were approved by Quidel’s stockholders at Quidel’s Special Meeting on May 16, 2022. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |